Home
    • Plans Blog Contact
    MaxCyte Inc logo

    MaxCyte Inc

    MXCT
    Last price US$1.32
    Market cap US$142.4m
    12M price change -5.71%
    Loading the 12-month Mave Thesis and 1-month news signal

    Industry and sector peers, plus broader research alternatives

    View comparison
    Abbott LaboratoriesABT Industry peer DexCom IncDXCM Industry peer Edwards Lifesciences CorpEW Industry peer Zoetis IncZTS Sector peer
    Overview Earnings Report Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Statements Financial Ratio
    Dashboard Funda..tals Prediction Screener Map

    MaxCyte Inc Overview

    Industry: Medical Devices

    Sector: Healthcare

    MaxCyte, Inc., a global life sciences company, discovers, develops, and commercializes next-generation cell therapies. The company's products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland. MaxCyte, Inc., a global life sciences company, discovers, develops, and commercializes next-generation cell therapies. The company's products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and Read More

    Mavefund brings filings, fundamentals, valuation, price history and news for MaxCyte Inc into one research view. The sections below show what strengthens or weakens the research case.

    Score

    Reported Results

    What the company reported, with filing details kept small.

    Filed Aug 12, 2026

    Quarterly result summary

    Revenue was $0.8M (+167% YoY). Net loss was -$8.9M (from $12.4M). Cash was $141.9M.

    Revenue $0.8M +167% YoY
    Net loss -$8.9M from $12.4M
    Cash $141.9M reported

    What changed

    • Revenue +167% YoY to $0.8M.
    • Net loss was -$8.9M (from $12.4M).

    Guidance / outlook

    No formal outlook was extracted from this filing excerpt. Open the SEC source to review full management commentary.

    Earnings release Open filing

    Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

    Other recent earnings materials
    SEC filing 10-Q Aug 13, 2026 SEC filing 8-K Aug 12, 2026 Earnings material Earnings release Aug 12, 2026 SEC filing 10-Q May 13, 2026 SEC filing 8-K May 12, 2026 Earnings release Earnings release May 12, 2026 Earnings material Earnings release May 12, 2026 SEC filing 10-K Mar 25, 2026 Earnings material Earnings release Mar 24, 2026 SEC filing 8-K Mar 24, 2026 Earnings release Earnings release Mar 24, 2026

    Prediction-grade evidence

    Recent News

    Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.

    Earnings Per Share

    Score 1.00/5
    MaxCyte Inc earns a low score, as its Earnings Per Share (EPS) has not shown continuous growth over the last six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    In Medical Devices industry , Abbott Laboratories , DexCom Inc , Edwards Lifesciences Corp are companies with high ratings.

    Return on Equity

    Score 1.95/5
    MaxCyte Inc exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    MaxCyte Inc MXCT US$142.4m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Net Margin

    Score 0.76/5
    MaxCyte Inc olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    MaxCyte Inc MXCT US$142.4m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Share Buyback

    In Medical Devices industry , Abbott Laboratories , DexCom Inc , Edwards Lifesciences Corp are companies with high ratings.

    Leverage

    Score 3.61/5
    MaxCyte Inc attains a commendable score in the category due to its lower leverage ratio over the past six years in comparison to the sector median value. Additionally, other notable companies in the same sector, such as Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc , also exhibit high scores.
    MaxCyte Inc MXCT US$142.4m
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Financial Statements

    Company-reported SEC EDGAR facts organized into the three core statements.

    Reported currency
    Verified SEC statements load when this section enters view.

    Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

    Financial Ratio

    Yearly Quarterly

    Financial
    Profitability
    Growth
    Cash Flow
    Financial Health
    Efficiency Ratios

    MaxCyte Inc logo

    MaxCyte Inc

    US$1.32

    US$142.4m

    12.82%

    -5.71%